Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study.

Merav Heshin-BekensteinAmit ZivNataša ToplakSiman LazauskasDanielle KadishevichEfrat Ben-Nun YaariAdi Miller-BarmakYonatan Butbul AvielEsther SaiagSara PelOri ElkayamYosef UzielVictoria Furer

Published in: Vaccines (2023)

The safety profile of three doses of the BNT162b2 mRNA vaccine was excellent, with adequate humoral response and similar efficacy among patients and controls. These results support the recommendation for vaccinating adolescents with juvenile-onset AIIRDs against COVID-19.

Keyphrases

coronavirus disease
sars cov
young adults
physical activity
immune response
binding protein
multiple sclerosis
respiratory syndrome coronavirus
oxidative stress